Alexander Gintsburg, director of the Gamaleya Epidemiology and Microbiology Research Center, announced the high effectiveness of the nasal vaccine developed by the center’s experts against coronavirus. Related reports DEA News”.
“We see that the currently available and currently registered nasal vaccine shows high efficiency in protecting against all strains and confers mucosal immunity against the pathogen,” Gunzburg said. Said.
Old Günzburg reportedHe said the vaccine to protect against new Omicron variants is based on the same platform as Sputnik V.
He explained that the vaccine includes a range of “delta” and “omicron” strains and should provide good protection against both these strains and the BA. bring out in Russia in June.
Prior to that, Russian scientists from the Institute of Experimental Medicine and Biotechnology Company BIOCAD developed Nasal vaccine candidate to help provide long-term immunity against coronavirus and influenza virus.